the new ewgsop2 consensus on sarcopenia€¦ · conceptual advances in sarcopenia muscle mass +...
TRANSCRIPT
![Page 1: The new EWGSOP2 consensus on sarcopenia€¦ · Conceptual advances in sarcopenia Muscle mass + function Syndromic approach Adverse ... GLENCORSE, Abbott Nutrition International (Observers)](https://reader033.vdocument.in/reader033/viewer/2022051510/5fff9437fa52d86383480749/html5/thumbnails/1.jpg)
The new EWGSOP2 consensus on sarcopenia
Alfonso J. Cruz-JentoftHospital Universitario Ramón y Cajal (IRYCIS)
Madrid, Spagna
![Page 2: The new EWGSOP2 consensus on sarcopenia€¦ · Conceptual advances in sarcopenia Muscle mass + function Syndromic approach Adverse ... GLENCORSE, Abbott Nutrition International (Observers)](https://reader033.vdocument.in/reader033/viewer/2022051510/5fff9437fa52d86383480749/html5/thumbnails/2.jpg)
2
CONFLICT OF INTEREST DISCLOSURE
I have the following potential conflicts of interest to report:
- Speaker fees from Abbott Nutrition, Fresenius, Nestlé, Nutricia, Sanofi-Aventis.
- Member of advisory boards: Abbott Nutrition, Boehringer IngelheimPharma, Nestlé, Pfizer, Regeneron, Rejuvenate.
- Research projects with Novartis, Nutricia, Regeneron.
![Page 3: The new EWGSOP2 consensus on sarcopenia€¦ · Conceptual advances in sarcopenia Muscle mass + function Syndromic approach Adverse ... GLENCORSE, Abbott Nutrition International (Observers)](https://reader033.vdocument.in/reader033/viewer/2022051510/5fff9437fa52d86383480749/html5/thumbnails/3.jpg)
3
First steps
"Sarcopenia" is a generic term for the loss of skeletal muscle mass, quality, and strength that can lead to frailty in the elderly.
1st Workshop on Sarcopenia – NIASeptember 19-21, 1994
Holloszy JO. Workshop on sarcopenia: muscle atrophy in old age. J Gerontol 1995 50A:(special issue) 1-161.
![Page 4: The new EWGSOP2 consensus on sarcopenia€¦ · Conceptual advances in sarcopenia Muscle mass + function Syndromic approach Adverse ... GLENCORSE, Abbott Nutrition International (Observers)](https://reader033.vdocument.in/reader033/viewer/2022051510/5fff9437fa52d86383480749/html5/thumbnails/4.jpg)
There is no universally agreed definition of sarcopenia
Source: Google Scholar, accessed November 6th, 2018
• EWGSOP (2010): 5287 citations
• IWGS (2011): 1488 citations
• AWGS (2014): 935 citations
• FNIH (2014): 535 citations
![Page 5: The new EWGSOP2 consensus on sarcopenia€¦ · Conceptual advances in sarcopenia Muscle mass + function Syndromic approach Adverse ... GLENCORSE, Abbott Nutrition International (Observers)](https://reader033.vdocument.in/reader033/viewer/2022051510/5fff9437fa52d86383480749/html5/thumbnails/5.jpg)
Human muscles
600 muscles in human body
Skeletal muscles: 40-45% of total body mass
55% of skeletal muscle mass in lower limbs
50% of total body protein is in muscles
Frontera WR et al. In: Physical Medicine&Rehabilitation. DeLisa JA (ed). LWW 2005
![Page 6: The new EWGSOP2 consensus on sarcopenia€¦ · Conceptual advances in sarcopenia Muscle mass + function Syndromic approach Adverse ... GLENCORSE, Abbott Nutrition International (Observers)](https://reader033.vdocument.in/reader033/viewer/2022051510/5fff9437fa52d86383480749/html5/thumbnails/6.jpg)
2010
This year, there was a major change in theconcept of sarcopenia
![Page 7: The new EWGSOP2 consensus on sarcopenia€¦ · Conceptual advances in sarcopenia Muscle mass + function Syndromic approach Adverse ... GLENCORSE, Abbott Nutrition International (Observers)](https://reader033.vdocument.in/reader033/viewer/2022051510/5fff9437fa52d86383480749/html5/thumbnails/7.jpg)
2010
April 2010
April 2010
May 2011
July 2011
Musclemass
AND
Musclefunction
![Page 8: The new EWGSOP2 consensus on sarcopenia€¦ · Conceptual advances in sarcopenia Muscle mass + function Syndromic approach Adverse ... GLENCORSE, Abbott Nutrition International (Observers)](https://reader033.vdocument.in/reader033/viewer/2022051510/5fff9437fa52d86383480749/html5/thumbnails/8.jpg)
Do we need an update of the 2010 definition of sarcopenia?
![Page 9: The new EWGSOP2 consensus on sarcopenia€¦ · Conceptual advances in sarcopenia Muscle mass + function Syndromic approach Adverse ... GLENCORSE, Abbott Nutrition International (Observers)](https://reader033.vdocument.in/reader033/viewer/2022051510/5fff9437fa52d86383480749/html5/thumbnails/9.jpg)
Conceptual advances in sarcopenia
Musclemass +
function
Syndromic approach
Adverse outcomes
Degreesof severity
![Page 10: The new EWGSOP2 consensus on sarcopenia€¦ · Conceptual advances in sarcopenia Muscle mass + function Syndromic approach Adverse ... GLENCORSE, Abbott Nutrition International (Observers)](https://reader033.vdocument.in/reader033/viewer/2022051510/5fff9437fa52d86383480749/html5/thumbnails/10.jpg)
So…where is the problem?
![Page 11: The new EWGSOP2 consensus on sarcopenia€¦ · Conceptual advances in sarcopenia Muscle mass + function Syndromic approach Adverse ... GLENCORSE, Abbott Nutrition International (Observers)](https://reader033.vdocument.in/reader033/viewer/2022051510/5fff9437fa52d86383480749/html5/thumbnails/11.jpg)
Problems to be addressed
• Sarcopenia begins earlier in life (important for interventions and prevention).
• Conceptualization of sarcopenia as a muscle disease.
• Problems in accurately measuring and categorizing muscle massand muscle quality.
• Outcome measures for interventions not agreed.
• SARCOPENIA HAS NOT REACHED MAINSTREAM CLINICAL PRACTICE (is it still too complicated)?
![Page 12: The new EWGSOP2 consensus on sarcopenia€¦ · Conceptual advances in sarcopenia Muscle mass + function Syndromic approach Adverse ... GLENCORSE, Abbott Nutrition International (Observers)](https://reader033.vdocument.in/reader033/viewer/2022051510/5fff9437fa52d86383480749/html5/thumbnails/12.jpg)
Parameters VariablesMeasurement
instrumentCutoff-points
Muscle mass
Muscle strength
Physical performance?Mass: total? regional? appendicular? single muscle?
Muscle strength: where? single or groups?
… Muscle mass: anthropometry? BIA? DXA? CT? MRI?
Biochemistry? Protocols, equations, assumptions
…Cutoff points for each variable and instrument:
reference populations? local or global?
…
OUTCOME VARIABLES
Performance, mobility, ADL, falls, NH admission, PRO…
![Page 13: The new EWGSOP2 consensus on sarcopenia€¦ · Conceptual advances in sarcopenia Muscle mass + function Syndromic approach Adverse ... GLENCORSE, Abbott Nutrition International (Observers)](https://reader033.vdocument.in/reader033/viewer/2022051510/5fff9437fa52d86383480749/html5/thumbnails/13.jpg)
EUROPEAN WORKING GROUPON SARCOPENIA IN OLDER PEOPLE
An update of the 2010 definition
¡¡¡ BIENVENIDOS !!!
![Page 14: The new EWGSOP2 consensus on sarcopenia€¦ · Conceptual advances in sarcopenia Muscle mass + function Syndromic approach Adverse ... GLENCORSE, Abbott Nutrition International (Observers)](https://reader033.vdocument.in/reader033/viewer/2022051510/5fff9437fa52d86383480749/html5/thumbnails/14.jpg)
Alcalá de HenaresUniversity founded 1293
![Page 15: The new EWGSOP2 consensus on sarcopenia€¦ · Conceptual advances in sarcopenia Muscle mass + function Syndromic approach Adverse ... GLENCORSE, Abbott Nutrition International (Observers)](https://reader033.vdocument.in/reader033/viewer/2022051510/5fff9437fa52d86383480749/html5/thumbnails/15.jpg)
2018 EWGSOP
Alfonso J. CRUZ-JENTOFT, SpainGülistan BAHAT, TurkeyJürgen BAUER, GermanyYves BOIRIE, FranceOlivier BRUYÉRE, BelgiumTommy CEDERHOLM, SwedenCyrus COOPER, UKFrancesco LANDI, ItalyYves ROLAND, FranceAvan SAYER, UK
Stephane SCHNEIDER, FranceCornel SIEBER, GermanyEva TOPINKOVÁ, Czech RepublicMaurits VANDEWOUDE, BelgiumMarjolein VISSER, NetherlandsMauro ZAMBONI, Italy
Cecilia HOFFMAN, Medical Writer
Ricardo RUEDA + Carole GLENCORSE, Abbott Nutrition International (Observers)
WRITING GROUP
![Page 16: The new EWGSOP2 consensus on sarcopenia€¦ · Conceptual advances in sarcopenia Muscle mass + function Syndromic approach Adverse ... GLENCORSE, Abbott Nutrition International (Observers)](https://reader033.vdocument.in/reader033/viewer/2022051510/5fff9437fa52d86383480749/html5/thumbnails/16.jpg)
Ivan BAUTMANS, BelgiumJean Pierre BAEYENS, BelgiumMatteo CESARI, ItalyAntonio CHERUBINI, ItalyJohn KANIS, UKMarcello MAGGIO, ItalyFinbarr MARTIN, UK
Jean-Pierre MICHEL, SwitzerlandKaisu PITKALA, FinlandJean-Yves REGINSTER, BelgiumRené RIZZOLI, SwitzerlandMª Dolores SÁNCHEZ, SpainJos SCHOLS, Netherlands
EXTENDED GROUP2018 EWGSOP
![Page 17: The new EWGSOP2 consensus on sarcopenia€¦ · Conceptual advances in sarcopenia Muscle mass + function Syndromic approach Adverse ... GLENCORSE, Abbott Nutrition International (Observers)](https://reader033.vdocument.in/reader033/viewer/2022051510/5fff9437fa52d86383480749/html5/thumbnails/17.jpg)
2018 EWGSOP
![Page 18: The new EWGSOP2 consensus on sarcopenia€¦ · Conceptual advances in sarcopenia Muscle mass + function Syndromic approach Adverse ... GLENCORSE, Abbott Nutrition International (Observers)](https://reader033.vdocument.in/reader033/viewer/2022051510/5fff9437fa52d86383480749/html5/thumbnails/18.jpg)
Endorsing societies
![Page 19: The new EWGSOP2 consensus on sarcopenia€¦ · Conceptual advances in sarcopenia Muscle mass + function Syndromic approach Adverse ... GLENCORSE, Abbott Nutrition International (Observers)](https://reader033.vdocument.in/reader033/viewer/2022051510/5fff9437fa52d86383480749/html5/thumbnails/19.jpg)
![Page 20: The new EWGSOP2 consensus on sarcopenia€¦ · Conceptual advances in sarcopenia Muscle mass + function Syndromic approach Adverse ... GLENCORSE, Abbott Nutrition International (Observers)](https://reader033.vdocument.in/reader033/viewer/2022051510/5fff9437fa52d86383480749/html5/thumbnails/20.jpg)
Definition of sarcopenia
Sarcopenia is a progressive and generalized skeletal muscle disorderthat is associated with increased likelihood of adverse outcomesincluding falls, fractures, physical disability, and mortality.
Muscle failure
![Page 21: The new EWGSOP2 consensus on sarcopenia€¦ · Conceptual advances in sarcopenia Muscle mass + function Syndromic approach Adverse ... GLENCORSE, Abbott Nutrition International (Observers)](https://reader033.vdocument.in/reader033/viewer/2022051510/5fff9437fa52d86383480749/html5/thumbnails/21.jpg)
Operational definition of sarcopenia:EWGSOP
LOW MUSCLE
MASS
LOW PHYSICAL PERFORMANCE
LOW MUSCLE STRENGH
AND/OR SARCOPENIA
![Page 22: The new EWGSOP2 consensus on sarcopenia€¦ · Conceptual advances in sarcopenia Muscle mass + function Syndromic approach Adverse ... GLENCORSE, Abbott Nutrition International (Observers)](https://reader033.vdocument.in/reader033/viewer/2022051510/5fff9437fa52d86383480749/html5/thumbnails/22.jpg)
New operational definition of sarcopenia:EWGSOP2
LOW MUSCLE QUANTITY/
QUALITY
LOW PHYSICAL PERFORMANCE
LOW MUSCLE STRENGH
PROBABLE
SARCOPENIASEVERE
SARCOPENIA
DEFINITE
SARCOPENIA
![Page 23: The new EWGSOP2 consensus on sarcopenia€¦ · Conceptual advances in sarcopenia Muscle mass + function Syndromic approach Adverse ... GLENCORSE, Abbott Nutrition International (Observers)](https://reader033.vdocument.in/reader033/viewer/2022051510/5fff9437fa52d86383480749/html5/thumbnails/23.jpg)
Case finding
• In clinical practice, case-finding may start when a patient reportssymptoms or signs of sarcopenia (i.e., falling, feeling weak, slowwalking speed, difficulty rising from a chair, or weight loss/musclewasting). In such cases, further testing for sarcopenia isrecommended.
• EWGSOP2 recommends use of the SARC-F questionnaire as a wayto elicit self-reports.
![Page 24: The new EWGSOP2 consensus on sarcopenia€¦ · Conceptual advances in sarcopenia Muscle mass + function Syndromic approach Adverse ... GLENCORSE, Abbott Nutrition International (Observers)](https://reader033.vdocument.in/reader033/viewer/2022051510/5fff9437fa52d86383480749/html5/thumbnails/24.jpg)
Measuring sarcopenia parameters
MU
SCLE
STR
ENG
TH • Handgripstrength
• Chairstand test
MU
SCLE
QU
AN
TITY • DXA
• (BIA)
• CT / MRI
PH
YSI
CA
L P
ERFO
RM
AN
CE • Gait
speed
• SPPB
• TUG
• 400 m walk
![Page 25: The new EWGSOP2 consensus on sarcopenia€¦ · Conceptual advances in sarcopenia Muscle mass + function Syndromic approach Adverse ... GLENCORSE, Abbott Nutrition International (Observers)](https://reader033.vdocument.in/reader033/viewer/2022051510/5fff9437fa52d86383480749/html5/thumbnails/25.jpg)
Alternative and new tools
• Lumbar 3rd vertebra imaging by computed tomography
• Mid-thigh muscle measurement
• Psoas muscle measurement with computed tomography
• Muscle quality measurements?
• Creatine dilution test
• Ultrasound assessment of muscle
• Specific biomarkers or panels of biomarkers
• SarQoL questionnaire
![Page 26: The new EWGSOP2 consensus on sarcopenia€¦ · Conceptual advances in sarcopenia Muscle mass + function Syndromic approach Adverse ... GLENCORSE, Abbott Nutrition International (Observers)](https://reader033.vdocument.in/reader033/viewer/2022051510/5fff9437fa52d86383480749/html5/thumbnails/26.jpg)
Cut-off points!Test Cut-off points for
men
Cut-off points for
women
References
EWGSOP2 sarcopenia cutoff points for low strength by chair stand and grip
strength
Grip strength <27 kg <16 kg Dodds, 2014[26]
Chair stand >15 sec for 5 rises Cesari, 2009[67]
EWGSOP sarcopenia cut-off points for low muscle quantity
ASM < 20 kg < 15 kg Studenski,
2014[3]
ASM/height2 < 7.0 kg/m2 < 5.5 kg/m2 Gould,
2014[125]
![Page 27: The new EWGSOP2 consensus on sarcopenia€¦ · Conceptual advances in sarcopenia Muscle mass + function Syndromic approach Adverse ... GLENCORSE, Abbott Nutrition International (Observers)](https://reader033.vdocument.in/reader033/viewer/2022051510/5fff9437fa52d86383480749/html5/thumbnails/27.jpg)
Cut-off points!Test Cut-off points
for men
Cut-off points
for women
References
EWGSOP sarcopenia cut-off points for low performance
Gait speed ≤ 0.8 m/sec Cruz-Jentoft,
2010[1]
Studenski,
2011[84]
SPPB ≤ 8 point score Pavasini,
2016[90]
Guralnik,
1995[126]
TUG ≥ 20 sec Bischoff,
2003[127]
400m walk test Non-completion or ≥ 6 min for
completion
Newman,
2006[128]
![Page 28: The new EWGSOP2 consensus on sarcopenia€¦ · Conceptual advances in sarcopenia Muscle mass + function Syndromic approach Adverse ... GLENCORSE, Abbott Nutrition International (Observers)](https://reader033.vdocument.in/reader033/viewer/2022051510/5fff9437fa52d86383480749/html5/thumbnails/28.jpg)
New algorithm
![Page 29: The new EWGSOP2 consensus on sarcopenia€¦ · Conceptual advances in sarcopenia Muscle mass + function Syndromic approach Adverse ... GLENCORSE, Abbott Nutrition International (Observers)](https://reader033.vdocument.in/reader033/viewer/2022051510/5fff9437fa52d86383480749/html5/thumbnails/29.jpg)
Early lifeMaximize peak
Age
Mu
scle
str
en
gth
Adult lifeMaintain peak
Older lifeMinimize loss
Threshold of disability
Threshold of low physical performanceRange of strength
in individuals
Time course
![Page 30: The new EWGSOP2 consensus on sarcopenia€¦ · Conceptual advances in sarcopenia Muscle mass + function Syndromic approach Adverse ... GLENCORSE, Abbott Nutrition International (Observers)](https://reader033.vdocument.in/reader033/viewer/2022051510/5fff9437fa52d86383480749/html5/thumbnails/30.jpg)
Aging
Disease
Inactivity
Malnutrition
• Age-associated muscle loss
• Inflammatory conditions (e.g., organ failure, malignancy)
• Osteoarthritis• Neurological disorders
• Sedentary behavior (e.g., limited mobility or bedrest)
• Physical inactivity
• Under-nutrition or malabsorption• Medication-related anorexia• Over-nutrition/obesity
Sarcopenia categories
![Page 31: The new EWGSOP2 consensus on sarcopenia€¦ · Conceptual advances in sarcopenia Muscle mass + function Syndromic approach Adverse ... GLENCORSE, Abbott Nutrition International (Observers)](https://reader033.vdocument.in/reader033/viewer/2022051510/5fff9437fa52d86383480749/html5/thumbnails/31.jpg)
Acute and chronic sarcopenia
• Acute sarcopenia: less than 6 months.
• Usually related to an acute illness or injury.
• Chronic sarcopenia: sarcopenia lasting ≥ 6 months.
• Comes with chronic and progressive conditions.
• Underscored the need to conduct periodic sarcopenia assessmentsin individuals at risk.
• May facilitate early intervention.
![Page 32: The new EWGSOP2 consensus on sarcopenia€¦ · Conceptual advances in sarcopenia Muscle mass + function Syndromic approach Adverse ... GLENCORSE, Abbott Nutrition International (Observers)](https://reader033.vdocument.in/reader033/viewer/2022051510/5fff9437fa52d86383480749/html5/thumbnails/32.jpg)
Some gaps in research
How can we identify older persons at high risk of sarcopenia?
Need of normative data to define validated cut-off points
Management of stature-, gender- and region-dependent measures.
What muscle quality indicators best predict outcomes?
What are the kinetics of muscle loss?
What outcomes are best used as sensitive measures of response to sarcopenia treatments?
![Page 33: The new EWGSOP2 consensus on sarcopenia€¦ · Conceptual advances in sarcopenia Muscle mass + function Syndromic approach Adverse ... GLENCORSE, Abbott Nutrition International (Observers)](https://reader033.vdocument.in/reader033/viewer/2022051510/5fff9437fa52d86383480749/html5/thumbnails/33.jpg)
33
![Page 34: The new EWGSOP2 consensus on sarcopenia€¦ · Conceptual advances in sarcopenia Muscle mass + function Syndromic approach Adverse ... GLENCORSE, Abbott Nutrition International (Observers)](https://reader033.vdocument.in/reader033/viewer/2022051510/5fff9437fa52d86383480749/html5/thumbnails/34.jpg)
34
![Page 35: The new EWGSOP2 consensus on sarcopenia€¦ · Conceptual advances in sarcopenia Muscle mass + function Syndromic approach Adverse ... GLENCORSE, Abbott Nutrition International (Observers)](https://reader033.vdocument.in/reader033/viewer/2022051510/5fff9437fa52d86383480749/html5/thumbnails/35.jpg)
35
Compared with the nonosteosarcopenic group, those with osteosarcopenia had greater impairmentof physical performance and balance.
The EWGSOP2 and FNIH criteria resulted in thestrongest associations with physical performance and self-reported falls and fractures.
![Page 36: The new EWGSOP2 consensus on sarcopenia€¦ · Conceptual advances in sarcopenia Muscle mass + function Syndromic approach Adverse ... GLENCORSE, Abbott Nutrition International (Observers)](https://reader033.vdocument.in/reader033/viewer/2022051510/5fff9437fa52d86383480749/html5/thumbnails/36.jpg)
36
UK Biobank cohort
Prevalence of sarcopenia EWGSOP1 8.14%Prevalence of sarcopenia EWGSOP2 0.36%
![Page 37: The new EWGSOP2 consensus on sarcopenia€¦ · Conceptual advances in sarcopenia Muscle mass + function Syndromic approach Adverse ... GLENCORSE, Abbott Nutrition International (Observers)](https://reader033.vdocument.in/reader033/viewer/2022051510/5fff9437fa52d86383480749/html5/thumbnails/37.jpg)
37
Sarcopenia prevalence was 22.8% and 23.9% usingEWGSOP2 and FNIH criteria respectively, with a lowclassification agreement.
Only EWGSOP2 definition predicted 3-years mortality (HR 1.84).
![Page 38: The new EWGSOP2 consensus on sarcopenia€¦ · Conceptual advances in sarcopenia Muscle mass + function Syndromic approach Adverse ... GLENCORSE, Abbott Nutrition International (Observers)](https://reader033.vdocument.in/reader033/viewer/2022051510/5fff9437fa52d86383480749/html5/thumbnails/38.jpg)
SUMMARY
![Page 39: The new EWGSOP2 consensus on sarcopenia€¦ · Conceptual advances in sarcopenia Muscle mass + function Syndromic approach Adverse ... GLENCORSE, Abbott Nutrition International (Observers)](https://reader033.vdocument.in/reader033/viewer/2022051510/5fff9437fa52d86383480749/html5/thumbnails/39.jpg)
Honorary Editor-in-ChiefJean-Pierre MichelMedical School, Geneva University, Switzerland
Associate EditorsHidenori Arai, National Center for Geriatrics and Gerontology, Obu (Aichi), JapanAntonio Cherubini, IRCCS-INRCA Ancona, ItalyPeter Crome, UCL Primary Care, London, UKHelen Roberts, University of Southampton, Southampton, UKTimo Strandberg, University of Helsinki, Helsinki, Finland
Editor-in-ChiefAlfonso J. Cruz-JentoftHospital Universitario Ramón y Cajal, Madrid, Spain
Please sign for the ToC!
![Page 40: The new EWGSOP2 consensus on sarcopenia€¦ · Conceptual advances in sarcopenia Muscle mass + function Syndromic approach Adverse ... GLENCORSE, Abbott Nutrition International (Observers)](https://reader033.vdocument.in/reader033/viewer/2022051510/5fff9437fa52d86383480749/html5/thumbnails/40.jpg)
WRITING GROUP
EXTENDED GROUP